Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Change in Cash: 2010-2025

Historic Change in Cash for Northwest Biotherapeutics (NWBO) over the last 15 years, with Sep 2025 value amounting to $244,000.

  • Northwest Biotherapeutics' Change in Cash rose 320.69% to $244,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year increase of 151.33%. This contributed to the annual value of $49,000 for FY2024, which is 101.01% up from last year.
  • As of Q3 2025, Northwest Biotherapeutics' Change in Cash stood at $244,000, which was down 84.12% from $1.5 million recorded in Q2 2025.
  • Northwest Biotherapeutics' 5-year Change in Cash high stood at $11.3 million for Q4 2021, and its period low was -$8.2 million during Q1 2022.
  • Moreover, its 3-year median value for Change in Cash was $244,000 (2025), whereas its average is -$218,636.
  • Per our database at Business Quant, Northwest Biotherapeutics' Change in Cash plummeted by 741.58% in 2021 and then soared by 5,789.74% in 2022.
  • Quarterly analysis of 5 years shows Northwest Biotherapeutics' Change in Cash stood at $11.3 million in 2021, then plummeted by 121.71% to -$2.5 million in 2022, then tumbled by 61.42% to -$4.0 million in 2023, then spiked by 80.76% to -$764,000 in 2024, then skyrocketed by 320.69% to $244,000 in 2025.
  • Its Change in Cash stands at $244,000 for Q3 2025, versus $1.5 million for Q2 2025 and $604,000 for Q1 2025.